ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pitavastatin

Also written as “Pitavastatin”, “Pitavastatin (NK-104)” and “NK-104-CR”.

Its studies are mostly in Hypercholesterolemia · Hyperlipidemias · Renal Insufficiency · Dyslipidemias · Diabetes Mellitus, Type 2, led by 5 companies.

Drug pagePitavastatin: every studyMany companies study it; this page follows only the 29 they lead. All 75 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Dec 18, 200929 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Kowaits history only180 open or runningphase 4since Dec 18, 2009Nov 4, 2005none ahead
JW Pharmaceutical80 open or runningphase 4since Mar 18, 2008Mar 18, 2008none ahead
Merckits history only10 open or runningphase 1since Oct 12, 2017Oct 12, 2017none ahead
Orient Pharmaits history only10 open or runningphase 3since Oct 16, 2012Oct 16, 2012none ahead
Tai Tien Pharmaceuticalsits history only10 open or runningphase 3since Jun 29, 2011Jun 29, 2011none ahead

Also a collaborator on its studies: Orient Europharma, Kowa Pharmaceuticals America and Eli Lilly.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of JW Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 18, 2008First study: phase 4 study in HypercholesterolemiaFirst studyNCT00640276 · 187 enrolled · Korea, Republic of
  2. Jun 17, 2008Phase 4 study in Heart FailureNCT00701285 · 70 enrolled · Korea, Republic of
  3. Nov 5, 2008Phase 4 study in Angina, StableNCT00786734 · Korea, Republic of
  4. Apr 27, 2009Phase 4 study in Hypercholesterolemia With Type2DMNCT00889226 · 161 enrolled
  5. Jul 19, 2010Phase 4 study in HypercholesterolemiaNCT01166633 · 200 enrolled
  6. Jul 26, 2011Phase 1 study in HyperlipidemiasNCT01406431 · 48 enrolled · Korea, Republic of
  7. Feb 4, 2014Phase 4 study in HyperlipidemiasNCT02056847 · 313 enrolled · Korea, Republic of
  8. Oct 6, 2020Phase 3 study in Primary HypercholesterolemiaNCT04584736 · 283 enrolled · Korea, Republic of

TargetBeta

HMGCR →read by rule
“HMG-CoA reductase inhibitor; HMG-CoA reductase inhibitor; HMG-CoA reductase inhibitor”ChEMBL 37, by rule

Other programs on HMGCR

ProgramCompanyFurthest phaseStudies
AtorvastatinruleViatrisphase 4186
rosuvastatinruleAstraZenecaphase 4184
SimvastatinruleOrganonphase 4100

Studies

All 8 JW Pharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04584736Primary Hypercholesterolemia · Korea, Republic of3CompletedJul 16, 2020283
NCT02056847Hyperlipidemias · Korea, Republic of4CompletedMay 2017313
NCT01406431Hyperlipidemias · Korea, Republic of1CompletedAug 201148
NCT01166633Hypercholesterolemia4CompletedNov 2010200
NCT00889226Hypercholesterolemia With Type2DM4CompletedMay 2009161
NCT00786734Angina, Stable · Korea, Republic of4WithdrawnMay 20090
NCT00701285Heart Failure · Korea, Republic of4CompletedMay 201370
NCT00640276Hypercholesterolemia · Korea, Republic of4CompletedFeb 2011187

How it is read

Names in the registry

  • “Pitavastatin”, 18 entries
  • “pitavastatin”, 8 entries
  • “Pitavastatin (NK-104)”, 3 entries
  • “NK-104-CR”, 2 entries
  • “pitavastatin single dose combined with ceftobiprole”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.